Richard Mauseth1, Sandra M Lord2, Irl B Hirsch3, Robert C Kircher4, Don P Matheson4, Carla J Greenbaum2. 1. Department of Pediatrics, University of Washington, Seattle, WA, USA Dose Safety, Inc, Seattle, WA, USA richardmausethmd@msn.com. 2. Benaroya Research Institute, Seattle, WA, USA. 3. School of Medicine, University of Washington, Seattle, WA, USA. 4. Dose Safety, Inc, Seattle, WA, USA.
Abstract
BACKGROUND: Under controlled conditions, the Dose Safety artificial pancreas (AP) system controller, which utilizes "fuzzy logic" (FL) methodology to calculate and deliver appropriate insulin dosages based on changes in blood glucose, successfully managed glycemic excursions. The aim of this study was to show whether stressing the system with pizza (high carbohydrate/high fat) meals and exercise would reveal deficits in the performance of the Dose Safety FL controller (FLC) and lead to improvements in the dosing matrix. METHODS: Ten subjects with type 1 diabetes (T1D) were enrolled and participated in 30 studies (17 meal, 13 exercise) using 2 versions of the FLC. After conducting 13 studies with the first version (FLC v2.0), interim results were evaluated and the FLC insulin-dosing matrix was modified to create a new controller version (FLC v2.1) that was validated through regression testing using v2.0 CGM datasets prior to its use in clinical studies. The subsequent 17 studies were performed using FLC v2.1. RESULTS: Use of FLC v2.1 vs FLC v2.0 in the pizza meal tests showed improvements in mean blood glucose (205 mg/dL vs 232 mg/dL, P = .04). FLC v2.1 versus FLC v2.0 in exercise tests showed improvements in mean blood glucose (146 mg/dL vs 201 mg/dL, P = .004), percentage time spent >180 mg/dL (19.3% vs 46.7%, P = .001), and percentage time spent 70-180 mg/dL (80.0% vs 53.3%, P = .002). CONCLUSION: Stress testing the AP system revealed deficits in the FLC performance, which led to adjustments to the dosing matrix followed by improved FLC performance when retested.
BACKGROUND: Under controlled conditions, the Dose Safety artificial pancreas (AP) system controller, which utilizes "fuzzy logic" (FL) methodology to calculate and deliver appropriate insulin dosages based on changes in blood glucose, successfully managed glycemic excursions. The aim of this study was to show whether stressing the system with pizza (high carbohydrate/high fat) meals and exercise would reveal deficits in the performance of the Dose Safety FL controller (FLC) and lead to improvements in the dosing matrix. METHODS: Ten subjects with type 1 diabetes (T1D) were enrolled and participated in 30 studies (17 meal, 13 exercise) using 2 versions of the FLC. After conducting 13 studies with the first version (FLC v2.0), interim results were evaluated and the FLC insulin-dosing matrix was modified to create a new controller version (FLC v2.1) that was validated through regression testing using v2.0 CGM datasets prior to its use in clinical studies. The subsequent 17 studies were performed using FLC v2.1. RESULTS: Use of FLC v2.1 vs FLC v2.0 in the pizza meal tests showed improvements in mean blood glucose (205 mg/dL vs 232 mg/dL, P = .04). FLC v2.1 versus FLC v2.0 in exercise tests showed improvements in mean blood glucose (146 mg/dL vs 201 mg/dL, P = .004), percentage time spent >180 mg/dL (19.3% vs 46.7%, P = .001), and percentage time spent 70-180 mg/dL (80.0% vs 53.3%, P = .002). CONCLUSION: Stress testing the AP system revealed deficits in the FLC performance, which led to adjustments to the dosing matrix followed by improved FLC performance when retested.
Authors: Howard Zisser; Eric Renard; Boris Kovatchev; Claudio Cobelli; Angelo Avogaro; Revital Nimri; Lalo Magni; Bruce A Buckingham; H Peter Chase; Francis J Doyle; John Lum; Peter Calhoun; Craig Kollman; Eyal Dassau; Anne Farret; Jerome Place; Marc Breton; Stacey M Anderson; Chiara Dalla Man; Simone Del Favero; Daniela Bruttomesso; Alessio Filippi; Rachele Scotton; Moshe Phillip; Eran Atlas; Ido Muller; Shahar Miller; Chiara Toffanin; Davide Martino Raimondo; Giuseppe De Nicolao; Roy W Beck Journal: Diabetes Technol Ther Date: 2014-07-08 Impact factor: 6.118
Authors: Richard Mauseth; Irl B Hirsch; Jennifer Bollyky; Robert Kircher; Don Matheson; Srinath Sanda; Carla Greenbaum Journal: Diabetes Technol Ther Date: 2013-07-05 Impact factor: 6.118
Authors: Richard Mauseth; Youqing Wang; Eyal Dassau; Robert Kircher; Donald Matheson; Howard Zisser; Lois Jovanovic; Francis J Doyle Journal: J Diabetes Sci Technol Date: 2010-07-01
Authors: Roman Hovorka; Daniela Elleri; Hood Thabit; Janet M Allen; Lalantha Leelarathna; Ranna El-Khairi; Kavita Kumareswaran; Karen Caldwell; Peter Calhoun; Craig Kollman; Helen R Murphy; Carlo L Acerini; Malgorzata E Wilinska; Marianna Nodale; David B Dunger Journal: Diabetes Care Date: 2014 Impact factor: 19.112
Authors: Steven J Russell; Firas H El-Khatib; Manasi Sinha; Kendra L Magyar; Katherine McKeon; Laura G Goergen; Courtney Balliro; Mallory A Hillard; David M Nathan; Edward R Damiano Journal: N Engl J Med Date: 2014-06-15 Impact factor: 91.245
Authors: Joon Bok Lee; Eyal Dassau; Ravi Gondhalekar; Dale E Seborg; Jordan E Pinsker; Francis J Doyle Journal: Ind Eng Chem Res Date: 2016-10-27 Impact factor: 3.720
Authors: Afroza Shirin; Fabio Della Rossa; Isaac Klickstein; John Russell; Francesco Sorrentino Journal: PLoS One Date: 2019-03-20 Impact factor: 3.240